Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single center in Wuhan, China
Xue et al.,
Hydroxychloroquine treatment in COVID-19: a descriptive observational analysis of 30 cases from a single..,
J. Med. Virology, June 17, 2020, doi:10.1002/jmv.26193
30 hospitalized patients. Early use of HCQ is more effective, 43% reduction in progression from moderate to severe. "Early" is relative here, within 7 days of hospitalization.
Xue et al., 17 Jun 2020, peer-reviewed, 7 authors.
Abstract: Xue Huiying
ORCID iD: 0000-0003-1050-3472
Accepted Article
Hydroxychloroquine treatment in COVID‐19: a
descriptive observational analysis of 30 cases from a
single center in Wuhan, China
Running title: Hydroxychloroquine treatment of 30 cases in wuhan
Huiying Xue*, Yi Liu*, Pan Luo, Xiulan Liu, Lin Qiu, Dong Liu, Juan Li
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China
Correspondence
Dong Liu and Juan Li, Department of
College, Huazhong University of Science and
Technology, 430030 Wuhan, China.
Email:
l_d2069@163.com (D. L.);
lijuan@tjh.tjmu.edu.cn (J. L.
Correspondence
Dong Liu and Juan Li, Department of
Pharmacy, Tongji Hospital, Tongji Medical
College, Huazhong University of Science and
Technology, 430030 Wuhan, China.
Email:
l_d2069@163.com (D. L.);
lijuan@tjh.tjmu.edu.cn (J. L.
This article has been accepted for publication and undergone full peer review but
has not been through the copyediting, typesetting, pagination and proofreading
process, which may lead to differences between this version and the Version of
Record. Please cite this article as doi: 10.1002/jmv.26193.
This article is protected by copyright. All rights reserved.
Correspondence
Dong Liu and Juan Li, Department of
Pharmacy, Tongji Hospital, Tongji Medical
Accepted Article
College, Huazhong University of Science and
Technology, 430030 Wuhan, China.
Email:
l_d2069@163.com (D. L.);
lijuan@tjh.tjmu.edu.cn (J. L.
Correspondence: Dong Liu and Juan Li, Department of Pharmacy, Tongji Hospital, Tongji
Medical College, Huazhong University of Science and Technology, 430030 Wuhan, China.
Email: l_d2069@163.com (D. L.); lijuan@tjh.tjmu.edu.cn (J. L.)
*List of corporate first authors
Abstract
Hydroxychloroquine (HCQ) garnered scientific attention in early February
following publication of reports showing in vitro activity of chloroquine (CQ)
against COVID-19. While studies are mixed on this topic, the therapeutic effect of
HCQ or CQ still need more valid clinical evidence. In this descriptive
observational study, we aimed to discuss the treatment response of HCQ in
COVID-19 infected patients and 30 cases were included. The demographic,
treatment, laboratory parameters of C-reactive protein (CRP) and interleukin-6
(IL-6) before and after HCQ therapy and clinical outcome in the 30 COVID-19
patients were assessed. In order to evaluate the effect of mediation time point, we
also divided these cases into two groups, patients began administrated with HCQ
within 7 days hospital (defined as early delivery group) and 7 days after hospital
(defined as later delivery group). We found that, the elevated IL-6, a risk factor in
severe patients were reduced to normal level after HCQ treatment. More
importantly, patients treated with HCQ at the time of early hospital recovered
faster than those who treated later or taken as second line choose for their obvious
shorter hospitalization time. In summary, early use of HCQ was better than later
use and the effect of IL-6 and CRP level can not be ruled out.
Key words: hydroxychloroquine; SARS-CoV-2; COVID-19; ACE2; cytokine
storms
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit